<DOC>
	<DOC>NCT00306787</DOC>
	<brief_summary>This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).</brief_summary>
	<brief_title>Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>At least 18 years old History of at least 4 recurrences of genital herpes in the preceding 12 months Lesions located on the external genitalia or anogenital region Willing to discontinue suppressive treatment Documented positive herpes simplex virus (HSV) General good health, and history of normal renal function Women of childbearing potential not using approved form of contraceptive Pregnant or nursing women History of hypersensitivity to famciclovir, valacyclovir, or acyclovir Known to be immunosuppressed Known to have renal dysfunction Receiving antiherpes therapy Known to have other genital tract disorders Known to have condition which could interfere with drug absorption Additional protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Herpes simplex</keyword>
	<keyword>genital herpes</keyword>
	<keyword>famciclovir</keyword>
	<keyword>valacyclovir</keyword>
	<keyword>Recurrent genital herpes</keyword>
</DOC>